Events Partner Content Cell and Gene Therapy Manufacturing Forum Last year we told you that the cell and gene industry would be worth $9 - $14 billion by 2026. We were wrong.
News J&J scores EU approval for Tecvayli combo in second line Johnson & Johnson's multiple myeloma regimen is now approved as a second line treatment in both the US and the EU.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.